Lipocine (LPCN) Change in Receivables (2012 - 2013)
Lipocine's (LPCN) quarterly Change in Receivables came in at -$92732.0 in Q3 2013, up 68.16% YoY from -$55146.7 in Q3 2012, and up 67.22% on a QoQ basis from -$282884.0 in Q2 2013.
Lipocine (LPCN) Change in Receivables (2012 - 2013) Analysis & Trends
Lipocine (LPCN) has 2 years of Change in Receivables data on file, last reported at -$92732.0 in Q3 2013.
- Quarterly Change in Receivables rose 68.16% year-over-year to -$92732.0 in Q3 2013, while the trailing twelve-month figure through Jun 2014 was -$92732.0 (changed N/A YoY) and the FY2012 annual result came in at -$313753.0, changed N/A from the prior year.
- Change in Receivables grew to -$92732.0 in Q3 2013, from -$282884.0 in the prior quarter.
- In the past five years, Change in Receivables ranged from a high of $375616.0 in Q1 2013 to a low of -$291198.0 in Q3 2012.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -53.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 117.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 31.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 94.29 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 37.16 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Lipocine | 11.15 Mn | -12.76 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2013 | -92,732.00 |
| Sep 30, 2013 | -92,732.00 |
| Jun 30, 2013 | -282,884.00 |
| Jun 30, 2013 | -282,884.00 |
| Mar 31, 2013 | 375,616.00 |
| Mar 31, 2013 | 375,616.00 |
| Sep 30, 2012 | -291,198.00 |
| Sep 30, 2012 | -291,198.00 |